EN23

When a sulfonylurea is not tolerated or ineffective.

• Amaryl^®

EN167

For the treatment of people with type 2 diabetes:
- As monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.

• Invokana^®
• Januvia^®
• Jardiance^®
• Nesina^®
• Trajenta^®

EN148

For the treatment of people with type 2 diabetes:
- In combination with metformin, when a sulfonylurea is contraindicated, not tolerated or ineffective.

• Invokana^®
• Onglyza^®
• Januvia^®
• Jardiance^®
• Nesina^®
• Forxiga^®

EN149

For the treatment of people with type 2 diabetes:
- In combination with a sulfonylurea, when metformin is contraindicated, not tolerated or ineffective.

• Invokana^®
• Onglyza^®
• Nesina^®
• Forxiga^®

EN150

For the treatment of people with type 2 diabetes:
When a sulfonylurea is contraindicated, not tolerated or ineffective; AND
- When the daily doses of metformin have been stable for at least a month.

• Janumet^®
• Janumet^®XR
• Komboglyze^®
• Jentadueto^TM
• Kazano^TM
• Xigduo^®

EN179

For the treatment of type 2 diabetes, in combination with one or more antidiabetic agents, in persons with a history of atherosclerotic heart disease (ASIC) or atherosclerotic vascular disease (ASK) and whose glycated hemoglobin (HbA1c) is ≥ 7%.

The nature of atherosclerotic heart disease (MCAS) or atherosclerotic vascular disease (MVAS) should be provided upon request by the Régie.

• Jardiance^®

EN219

For the treatment of people with type 2 diabetes whose optimal maximum dose of metformin has been stable for at least one month.
Individuals must also meet the requirements of the recognized indication for the payment of empagliflozin.

• Synjardy^TM

Reimbursement
(exception drugs)

Ozempic^®

For the treatment of people with type 2 diabetes:

• In combination with metformin, for the treatment of people with type 2 diabetes.
• When a sulfonylurea is contraindicated, not tolerated or ineffective.
• Authorization is given for a maximum weekly dose of 1mg.
• Inefficacy means non-achievement of an HbA1c value tailored to the patient.

To note:

• Unlike other GLP-1RA (Victoza and Trulicity), your patients do not need to have tried an iDPP4 or have a BMI > 30 to start treatment.
• Both doses (0.5mg and 1mg) are reimbursed.

Victoza^®

For the treatment of people with type 2 diabetes:

• In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
• When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
• The maximum duration of each authorization is 12 months.
• At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
• Authorization is given for a maximum daily dose of 1.8 mg.
• Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Trulicity^®

For the treatment of people with type 2 diabetes:

• In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
• When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
• The maximum duration of each authorization is 12 months.
• At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
• Authorization is given for a maximum daily dose of 1.5 mg.
• Inefficacy means non-achievement of an HbA1c value tailored to the patient.